Medtronic agrees to buy carotid stent maker Contego Medical for $380 million

Medtronic agreed to acquire Contego Medical for $380 million, with potential additional payments. The deal includes Contego's Neuroguard IEP Direct System and Excipio thrombectomy devices. Medtronic expects the acquisition to close in its fiscal third quarter, with minimal EPS dilution in fiscal 2027 and 2028, and a neutral to accretive effect afterward. Contego's devices focus on carotid artery disease and peripheral thrombectomy.

Original reporting
Published Nov 17, 2026, 12:02 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 17, 2026, 10:27 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefMergers & acquisitions
Primary signal
$MDT
Bullish
high confidence
Mentioned
$MDT
Relevance
9/10
AlphAI data visualization · based on mlq.ai
Decision brief

The 30-second read

$MDTBullishMed
01

Why it matters

The acquisition adds newly FDA-approved carotid revascularization technology with integrated embolic protection and positions Excipio alongside Medtronic’s Liberant system, with management guiding minimal dilution to adjusted EPS in FY27-28 and neutral to accretive effects after that.

02

Market read

Traders can reassess Medtronic’s growth outlook and deal economics ahead of expected fiscal Q3 closing, using the disclosed purchase price and EPS dilution/accretion guidance.

03

What to watch

Contingent payments and the lack of disclosed upfront versus contingent split could increase uncertainty around total consideration and near-term cash flow.

Relevance 9/10Novelty 8/10Timing: closing expected in Medtronic fiscal Q3, subject to customary conditions

Background

Medtronic has been a minority investor in Contego since 2020 and previously announced an exclusive US distribution agreement in January 2025.

Company-level read

Ticker impact

$MDTBullishHigh confidence
Context

Medtronic agreed to buy Contego Medical for $380 million, adding the FDA-approved Neuroguard IEP Direct System and Excipio thrombectomy devices.

Expected impact

Likely positive bias as investors price in expanded device portfolio and a path to accretion after closing.

Evidence & confidence

The article discloses a specific acquisition price, included FDA-approved products, and stated EPS dilution expectations (minimal in FY27-28, neutral to accretive thereafter), which are direct inputs to valuation and deal-risk assessment.

Market effects

Strengthens Medtronic’s position in carotid revascularization and thrombectomy devices, potentially increasing competitive pressure in peripheral vascular interventions.

Primarily US medtech market impact via FDA-approved device commercialization and distribution expansion.

Could influence global peripheral vascular device competitive dynamics if the acquired platform scales beyond the US.

Counterpoint

The deal’s value may be less compelling if integration and regulatory or reimbursement dynamics delay commercialization of Neuroguard and Excipio.

Key entities

  • Medtronic

    US-listed medical device company agreeing to acquire Contego for $380 million.

  • Contego Medical

    Privately held carotid stent and thrombectomy device maker; seller in the transaction.

  • Neuroguard IEP Direct System

    FDA-approved transcarotid artery revascularization system with integrated embolic protection and flow reversal.

  • Excipio thrombectomy devices

    Thrombectomy devices included in the acquisition, to sit alongside Medtronic’s Liberant system.

Related articles

$MDTMed

Medtronic announces FDA clearance of general surgery procedures for the Hugo™ robotic-assisted surgery (RAS) system

Medtronic (NYSE: MDT) received FDA clearance for its Hugo™ robotic-assisted surgery system to perform general surgery procedures, including cholecystectomy and hernia repairs. The expansion covers 3.5 million annual U.S. surgeries. The system's modular design offers flexibility, and Medtronic aims to surpass 50,000 procedures globally by its fiscal year-end.

$MDTMedAI 8/10

Medtronic buys Contego Medical for $380 M, expanding access to next-generation carotid therapies

Medtronic plans to acquire Contego Medical for $380 million, expanding its carotid artery disease treatment portfolio. The deal includes Contego's FDA-approved Neuroguard IEP™ Direct System. Medtronic expects the acquisition to be minimally dilutive to adjusted EPS in FY27 and FY28, and neutral to accretive thereafter. The transaction is subject to closing conditions and expected to complete in Q3 FY25.

$MDTMedAI 8/10

Medtronic to buy Contego Medical for $380M

Medtronic plans to acquire Contego Medical, a privately held medical device company, for $380 million. The deal will expand Medtronic's carotid disease treatments and is expected to close in Q3 of its fiscal year. Medtronic expects minimal dilution to earnings in fiscal 2027 and 2028, then neutrality or accretion after that.